BioNote, Inc.
Research BioNote, Inc. (377740.KS) on Bullrun: market cap KRW 468.74B, dividend yield 5.0%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker377740.KS
- ExchangeKS
- CountrySouth Korea
- SectorHealthcare
- IndustryMedical Devices
- CurrencyKRW
- Market capKRW 468.74B
- Dividend yield5.0%
- Financial periodQ2 2026
- RevenueKRW 36.37B
- Net incomeKRW 9.07B
- Free cash flowKRW 23.85B
- Gross margin53.7%
Valuation Snapshot
latest market cap is KRW 468.74B; dividend yield is 5.0%.
Peer valuation comparison
Latest dividend yield is 5.01% versus a Healthcare sector median of 2.4% (108.7% above).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 468.74B | n/a | 4.9% | 228 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 228 KRW, yield 5.0%.
About BioNote, Inc.
BioNote, Inc., manufactures and sells in-vitro diagnostic animal medicines in South Korea. It offers animal diagnostics products, such as fluorescence immunoassay, molecular diagnostics, clinical biochemistry, rapid immunoassay, and enzyme-linked immunosorbent assay products. The company also provides bio-content products, including rapid immunoassay for humans, human intermediate goods, and bio-contents reagents. In addition, it engages in the production and sell of medical devices. BioNote, Inc.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is BioNote, Inc.'s market cap?
BioNote, Inc.'s market capitalization is KRW 468.74B.
Does BioNote, Inc. pay a dividend?
BioNote, Inc. has a dividend yield of 5.0%.
What does BioNote, Inc. do?
BioNote, Inc., manufactures and sells in-vitro diagnostic animal medicines in South Korea. It offers animal diagnostics products, such as fluorescence immunoassay, molecular diagnostics, clinical biochemistry, rapid immunoassay, and enzyme-linked immunosorbent assay products. The company also provides bio-content products, including rapid immunoassay for humans, human intermediate goods, and bio-contents reagents. In addition, it engages in the production and sell of medical devices. BioNote, Inc. was founded in 2003 and is headquartered in Hwaseong-si, South Korea.